ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2731

The Utility of Unbiased Metagenomic Next Generation Sequencing in the Management of Patients with CNS Vasculitis

Hiromichi Tamaki1, Michael R Wilson2, Leonard H. Calabrese3, Joseph L. DeRisi4 and Rula A Hajj-Ali5, 1Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, Cleveland, OH, 2Department of Neurology, UCSF, San Francisco, CA, 3Rheumatic & Immunologic Disease, Cleveland Clinic Foundation, Cleveland, OH, 4Biochemistry and Biophysics, UCSF, San Francisco, CA, 5Rheumatology, Cleveland Clinic Foundation, Cleveland, OH

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: CNS Vasculitis, Genetic Biomarkers, Infection and management

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Vasculitis Poster III: Other Vasculitis Syndromes

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

In the clinical approach to CNS vasculitis, exclusion of infection is of major concern as some microbes can cause vasculitis, and infections can complicate immunosuppressive therapy for CNS vasculitis. The yields of conventional microbiologic techniques to detect CNS infections from cerebrospinal fluid (CSF) are suboptimal, particularly for unusual organisms that may not be part of the differential diagnosis. Unbiased metagenomic next-generation sequencing (mNGS) is an emerging technique that offers an alternative, hypothesis-free approach for detecting CNS infections. Here we report on a pilot study to examine the utility of mNGS in the management of patients with CNS vasculitis.      

Methods:

Patients were recruited from our CNS registry at Cleveland Clinic. Total RNA was extracted from 250 uL of CSF, and cDNA sequencing libraries were prepared using random hexamer primers. NGS was performed on an Illumina HiSeq 2500 machine, and the resulting 10-20 million paired-end 150 nucleotide sequences were analyzed by a rapid computational pipeline for identifying all known viruses, bacteria, fungi and parasites. The patients received a regular medical care otherwise. The results of mNGS were compared with regular medical care.

Results:

The main results are summarized in Table 1.

mNGS was useful in the following cases. Patient 1 was presumptively diagnosed with an autoimmune CNS disease based on a negative extensive infectious work-up. The CSF fungal cultures were negative 3 times, but research-based mNGS detected Aspergillus spp. This result was confirmed with a clinical 18s rRNA fungal PCR. Two patients (2, 3) with established CNS vasculitis clinically deteriorated while appropriately treated with glucocorticoids and cyclophosphamide. mNGS did not identify an infection. The patients were treated successfully with escalation of immunosuppression. Patient 4 did not have the typical triad for Susac’s syndrome, and as a result, a viral etiology was of great concern. To the degree that mNGS can be shown to have good sensitivity, the negative mNGS result in this case, would help exclude any lingering concerns about a potential infectious etiology.      

Conclusion:

While these data are preliminary, mNGS may be useful to detect infectious pathogens that are novel or associated with a low yield with conventional diagnostic techniques in patients with CNS vasculitis. mNGS may be also useful to exclude opportunisitic infections in patients with CNS vasculitis arising in those treated with aggressive immunosuppression therapy. This technique is worth exploring in the larger cohort of patients with CNS vasculitis and patient recruitment is ongoing.


Disclosure: H. Tamaki, None; M. R. Wilson, None; L. H. Calabrese, None; J. L. DeRisi, None; R. A. Hajj-Ali, Abbvie, 8,Novartis Pharmaceutical Corporation, 5.

To cite this abstract in AMA style:

Tamaki H, Wilson MR, Calabrese LH, DeRisi JL, Hajj-Ali RA. The Utility of Unbiased Metagenomic Next Generation Sequencing in the Management of Patients with CNS Vasculitis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-utility-of-unbiased-metagenomic-next-generation-sequencing-in-the-management-of-patients-with-cns-vasculitis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-utility-of-unbiased-metagenomic-next-generation-sequencing-in-the-management-of-patients-with-cns-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology